Successful Treatment with Bortezomib for Refractory Thrombotic Thrombocytopenic Purpura Associated with Systemic Lupus Erythematosus

Thrombotic thrombocytopenic purpura (TTP) is a life- threatening disease that can be secondary to systemic lupus erythematosus (SLE). The fist- line treatments of TTP are steroid, immunosuppressor and plasm exchange (PE). However, some patients may have a poor response to these treatments. Bortezomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Ruyu, Zhou, Shuang, Wang, Jinuo, Yang, Huaxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984934/
https://www.ncbi.nlm.nih.gov/pubmed/36879832
http://dx.doi.org/10.2478/rir-2022-0036
_version_ 1784900843000037376
author Yan, Ruyu
Zhou, Shuang
Wang, Jinuo
Yang, Huaxia
author_facet Yan, Ruyu
Zhou, Shuang
Wang, Jinuo
Yang, Huaxia
author_sort Yan, Ruyu
collection PubMed
description Thrombotic thrombocytopenic purpura (TTP) is a life- threatening disease that can be secondary to systemic lupus erythematosus (SLE). The fist- line treatments of TTP are steroid, immunosuppressor and plasm exchange (PE). However, some patients may have a poor response to these treatments. Bortezomib is a selective proteasome inhibitor and widely used to treat patients with multiple myeloma (MM). In recent years, bortezomib has been used to treat patients with refractory TTP. Here we report a patient with refractory TTP associated with SLE and had a successful treatment with bortezomib.
format Online
Article
Text
id pubmed-9984934
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-99849342023-03-05 Successful Treatment with Bortezomib for Refractory Thrombotic Thrombocytopenic Purpura Associated with Systemic Lupus Erythematosus Yan, Ruyu Zhou, Shuang Wang, Jinuo Yang, Huaxia Rheumatol Immunol Res Case Report Thrombotic thrombocytopenic purpura (TTP) is a life- threatening disease that can be secondary to systemic lupus erythematosus (SLE). The fist- line treatments of TTP are steroid, immunosuppressor and plasm exchange (PE). However, some patients may have a poor response to these treatments. Bortezomib is a selective proteasome inhibitor and widely used to treat patients with multiple myeloma (MM). In recent years, bortezomib has been used to treat patients with refractory TTP. Here we report a patient with refractory TTP associated with SLE and had a successful treatment with bortezomib. Sciendo 2022-12-31 /pmc/articles/PMC9984934/ /pubmed/36879832 http://dx.doi.org/10.2478/rir-2022-0036 Text en © 2022 Ruyu Yan, Shuang Zhou, Jinuo Wang, Huaxia Yang, published by De Gruyter https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
spellingShingle Case Report
Yan, Ruyu
Zhou, Shuang
Wang, Jinuo
Yang, Huaxia
Successful Treatment with Bortezomib for Refractory Thrombotic Thrombocytopenic Purpura Associated with Systemic Lupus Erythematosus
title Successful Treatment with Bortezomib for Refractory Thrombotic Thrombocytopenic Purpura Associated with Systemic Lupus Erythematosus
title_full Successful Treatment with Bortezomib for Refractory Thrombotic Thrombocytopenic Purpura Associated with Systemic Lupus Erythematosus
title_fullStr Successful Treatment with Bortezomib for Refractory Thrombotic Thrombocytopenic Purpura Associated with Systemic Lupus Erythematosus
title_full_unstemmed Successful Treatment with Bortezomib for Refractory Thrombotic Thrombocytopenic Purpura Associated with Systemic Lupus Erythematosus
title_short Successful Treatment with Bortezomib for Refractory Thrombotic Thrombocytopenic Purpura Associated with Systemic Lupus Erythematosus
title_sort successful treatment with bortezomib for refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984934/
https://www.ncbi.nlm.nih.gov/pubmed/36879832
http://dx.doi.org/10.2478/rir-2022-0036
work_keys_str_mv AT yanruyu successfultreatmentwithbortezomibforrefractorythromboticthrombocytopenicpurpuraassociatedwithsystemiclupuserythematosus
AT zhoushuang successfultreatmentwithbortezomibforrefractorythromboticthrombocytopenicpurpuraassociatedwithsystemiclupuserythematosus
AT wangjinuo successfultreatmentwithbortezomibforrefractorythromboticthrombocytopenicpurpuraassociatedwithsystemiclupuserythematosus
AT yanghuaxia successfultreatmentwithbortezomibforrefractorythromboticthrombocytopenicpurpuraassociatedwithsystemiclupuserythematosus

Ejemplares similares